Compare TNET & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNET | MLYS |
|---|---|---|
| Founded | 1988 | 2019 |
| Country | United States | United States |
| Employees | 2700 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.1B |
| IPO Year | 2000 | 2023 |
| Metric | TNET | MLYS |
|---|---|---|
| Price | $45.54 | $25.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $65.80 | $48.67 |
| AVG Volume (30 Days) | 342.8K | ★ 1.9M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.57% | N/A |
| EPS Growth | N/A | ★ 37.43 |
| EPS | ★ 1.90 | N/A |
| Revenue | ★ $5,010,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.30 | N/A |
| P/E Ratio | $24.51 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.67 | $12.59 |
| 52 Week High | $76.09 | $47.65 |
| Indicator | TNET | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 50.50 | 44.59 |
| Support Level | $34.47 | $22.36 |
| Resistance Level | $45.62 | $31.29 |
| Average True Range (ATR) | 1.96 | 1.43 |
| MACD | -0.25 | -0.22 |
| Stochastic Oscillator | 5.05 | 28.15 |
Trinet Group Inc provides human resources solutions for small and medium-sized businesses through technology-enabled services. Its offerings include human capital expertise, employee benefits such as health insurance and retirement plans, payroll and payroll tax administration, risk mitigation, and compliance consulting. The company provides its services through professional employer organization (PEO) services delivered via a co-employment model, as well as administrative services organization (ASO) offerings. The majority of the company's revenue is derived from the insurance-related billings and administrative fees collected from PEO clients.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.